09989.HK
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 4.23
−0.59%Margins
Gross margin
33.3%
EBITDA margin
6.7%
EBIT margin
3.7%
Net margin
3.9%
FCF margin
27.1%
1.7%
Return on equity
1.2%
Return on assets
1.3%
Return on invested capital
0.31x
Asset turnover
HKD 1.7B
Cash from operations
HKD 2.82
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026